Secondary Endpoints

CAM211 Study Design

• Time-to-event parameters

  • Survival, duration of response, time to disease progression

• Clinical Benefit

  • Resolution of B-symptoms and fatigue
  • Resolution/reduction in massive splenomegaly

Previous slide

Next slide

Back to first slide

View graphic version